Grail's $950 Cancer Blood Test Shows Mixed Results in Early Detection
Grail, a healthcare company, presented its largest study on the Galleri blood test at the American Society of Clinical Oncology meeting. The test, priced at $950, aims to detect over 50 types of cancer early. The study involved over 140,000 participants and showed that while the test increased cancer detection, it missed many early-stage cancers. The test is not FDA-approved but is available with a prescription. Despite its limitations, the test is seen as promising for detecting certain cancers earlier than traditional methods. 
